1. A glucopyranosyloxybenzylbenzene derivative represented by the general formula:
9
wherein R1 represents a hydrogen atom, a hydroxy group, an amino group, a mono or di (lower alkyl) amino group, a carbamoyl group, a lower alkyl group, a lower alkoxy group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a carbamoyl (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy-substituted (lower alkylthio) group, a lower alkenyloxy group, an aralkyloxy group, a hydroxy(lower alkenyl) group, a carboxy group, a lower alkoxycarbonyl group, a cyano group, an aralkyloxy(lower alkyl) group, a cyano(lower alkyl) group, a carbamoyl group, a carbamoyl (lower alkyl) group, an amino group, a mono or di (lower alkyl)amino group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group; with the proviso that R3 does not represent a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group when R1 represents a hydrogen atom or a hydroxy(lower alkyl) group and R2 represents a hydrogen atom, or a pharmaceutically acceptable salt thereof.
2. A glucopyranosyloxybenzylbenzene derivative as claimed in claim 1 wherein R1 represents a hydrogen atom or a hydroxy(lower alkyl) group; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy-substituted (lower alkylthio) group, a lower alkenyloxy group, an aralkyloxy group, a hydroxy(lower alkenyl) group, a carboxy group, a lower alkoxycarbonyl group, a cyano group, an aralkyloxy(lower alkyl) group, a cyano(lower alkyl) group, a carbamoyl group, a carbamoyl (lower alkyl) group, an amino group, a mono or di(lower alkyl)amino group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group; with the proviso that R3 does not represent a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group when R1 represents a hydrogen atom or a hydroxy(lower alkyl) group and R2 represents a hydrogen atom, or a pharmaceutically acceptable salt thereof.
3. A glucopyranosyloxybenzylbenzene derivative as claimed in claim 1 wherein R1 represents a hydroxy group, an amino group, a mono or di (lower alkyl) amino group, a carbamoyl group, a lower alkyl group, a lower alkoxy group, a hydroxy(lower alkoxy) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a carbamoyl (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy-substituted (lower alkylthio) group, a lower alkenyloxy group, an aralkyloxy group, a hydroxy(lower alkenyl) group, a carboxy group, a lower alkoxycarbonyl group, a cyano group, an aralkyloxy(lower alkyl) group, a cyano(lower alkyl) group, a carbamoyl group, a carbamoyl (lower alkyl) group, an amino group, a mono or di (lower alkyl)amino group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group, or a pharmaceutically acceptable salt thereof.
4. A glucopyranosyloxybenzylbenzene derivative as claimed in claim 1 wherein R1 represents a hydrogen atom, a hydroxy group, an amino group, a mono or di (lower alkyl) amino group, a carbamoyl group, a lower alkyl group, a lower alkoxy group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a carbamoyl (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a lower alkenyloxy group, a hydroxy(lower alkenyl) group, a carbamoyl (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkyl) group or a carboxy(lower alkyl) group, or a pharmaceutically acceptable salt thereof.
5. A glucopyranosyloxybenzylbenzene derivative as claimed in claim 3 wherein R1 represents an amino group, a mono or di(lower alkyl) amino group, a carbamoyl group, a carbamoyl (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy-substituted (lower alkylthio) group, a lower alkenyloxy group, an aralkyloxy group, a hydroxy(lower alkenyl) group, a carboxy group, a lower alkoxycarbonyl group, a cyano group, an aralkyloxy(lower alkyl) group, a cyano(lower alkyl) group, a carbamoyl group, a carbamoyl (lower alkyl) group, an amino group, a mono or di (lower alkyl)amino group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group, or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising as an active ingredient a glucopyranosyloxybenzylbenzene derivative as claimed in claim 1-5 or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition as claimed in claim 6 wherein the composition is a human SGLT2 inhibitor.
8. A pharmaceutical composition as claimed in claim 7 wherein the composition is an agent for the prevention or treatment of a disease associated with hyperglycemia.
9. A pharmaceutical composition as claimed in claim 8 wherein a disease associated with hyperglycemia is diabetes or diabetic complication.
10. A pharmaceutical composition as claimed in claim 8 wherein a disease associated with hyperglycemia is obesity.
11. A method for the prevention or treatment of a disease associated with hyperglycemia, which comprises administering a therapeutically effective amount of a glucopyranosyloxybenzylbenzene derivative as claimed in claim 1-5 or a pharmaceutically acceptable salt thereof.
12. A use of a glucopyranosyloxybenzylbenzene derivative as claimed in claim 1-5 or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with hyperglycemia.
13. A benzylphenol derivative represented by the general formula:
10
wherein R11 represents a hydrogen atom, a protected hydroxy group, a protected amino group, a protected mono(lower alkyl)amino group, a di(lower alkyl)amino group, a carbamoyl group, a lower alkyl group, a lower alkoxy group, a protected hydroxy(lower alkyl) group, a protected hydroxy(lower alkoxy) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a carbamoyl (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group; R12 represents a hydrogen atom or a lower alkyl group; and R13 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a protected hydroxy(lower alkyl) group, a protected hydroxy(lower alkoxy) group, a protected hydroxy(lower alkylthio) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy-substituted (lower alkylthio) group, a lower alkenyloxy group, an aralkyloxy group, a protected hydroxy(lower alkenyl) group, a carboxy group, a lower alkoxycarbonyl group, a cyano group, an aralkyloxy(lower alkyl) group, a cyano(lower alkyl) group, a carbamoyl group, a carbamoyl (lower alkyl) group, an protected amino group, a protected mono(lower alkyl)amino group, a di(lower alkyl)amino group, a lower alkoxycarbonyl-substituted (lower alkyl) group, a lower alkoxycarbonyl-substituted (lower alkoxy) group, a carboxy(lower alkyl) group or a carboxy(lower alkoxy) group; with the proviso that R13 does not represent a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a protected hydroxy(lower alkyl) group, a protected hydroxy(lower alkoxy) group, a protected hydroxy(lower alkylthio) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group when R11 represents a hydrogen atom or a protected hydroxy(lower alkyl) group and R12 represents a hydrogen atom, or a salt thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A lithography system comprising:
a laser system configured to operate at an output pulse repetition rate of up to 12 kHz, the laser system comprising:
a seed laser oscillator producing an output comprising a laser output light beam of pulses, the seed laser oscillator comprising a first gas discharge laser chamber; and
a laser amplification stage containing an amplifying gain medium in a second gas discharge laser chamber receiving the output of the seed laser oscillator and amplifying the output of the seed laser oscillator to a pulse energy of \u22671 mJ to form a laser system output comprising a laser output light beam of pulses, the laser amplification stage comprising:
a regenerative closed loop optical cavity defined in part by a partially reflecting optical element through which the seed laser oscillator output light beam is injected, and
a beam de-magnification stage and a beam expansion stage within the optical cavity, wherein the beam de-magnification stage is configured to de-magnify the laser beam as the laser beam travels from the partially reflecting optical element toward the amplifying gain medium and the beam expansion stage is configured to expand the laser beam as the laser beam travels from the amplifying gain medium toward the partially reflecting optical element; and
a photolithography tool that receives the laser system output.
2. The system of claim 1, further comprising a coherence busting mechanism intermediate the seed laser oscillator and the laser amplification stage.
3. The system of claim 2, wherein the coherence busting mechanism includes an optical delay path having a delay length longer than the coherence length of a pulse in the seed laser oscillator laser output light beam of pulses.
4. The system of claim 1, further comprising a coherence busting mechanism within the photolithography tool.
5. The system of claim 1, wherein the beam expansion stage comprises at least one prism.
6. The system of claim 1, wherein the beam expansion stage comprises a two prism beam expander.
7. The system of claim 6, wherein the first prism of the two prism beam expander comprises a split prism and the second prism of the two prism beam expander comprises a one piece prism.
8. The system of claim 1, wherein the laser amplification stage is defined between a beam reverser and the partially reflecting optical element.
9. The system of claim 1, wherein the beam reverser comprises a prism that is configured to cross a light beam traveling along a first path through the amplifying gain medium with a light beam traveling along a second path through the amplifying gain medium.
10. The system of claim 1, further comprising:
a timing and energy controller selecting a differential timing between an electrical discharge between a pair of electrodes in the first laser chamber and in the second laser chamber to thereby maintain amplified spontaneous emission below a selected limit and the pulse energy of the laser system output light beam of pulses essentially constant.
11. The system of claim 10, wherein the seed laser oscillator includes a line narrowing module.
12. The system of claim 11, wherein the line narrowing module includes a bandwidth selection optic that is connected to the timing and energy controller to enable the controller to adjust the bandwidth of the pulses of the seed laser oscillator output light beam.
13. The system of claim 12, wherein:
the bandwidth selection optic comprises a grating; and
the controller is configured to cause a change in the shape of a face of the grating upon which is incident a pulse.
14. The system of claim 1, further comprising:
one or more additional laser systems designed identically to the laser system, each laser system operating at a pulsed rate of X kHz; and
a beam combining system configured to combine the output pulses from at least two of the pulsed laser systems to produce a laser system output having a laser output light beam of pulses at a pulse repetition rate of 2X kHz.
15. The system of claim 14, wherein the beam combining system comprises one or more pulse stretchers that receive the output pulses of the respective laser amplification stages.
16. The system of claim 14, wherein each of the laser systems provides output light pulse beams to the beam combining system in an overleaving fashion.
17. The system of claim 14, wherein each of the laser systems produces output pulses with interleaved firing times.
18. The system of claim 1, wherein the closed loop optical cavity comprises a bow-tie loop.
19. The system of claim 1, wherein the closed loop optical cavity comprises a race track loop.
20. The system of claim 1, wherein the seed laser oscillator comprises a line narrowing module.